Our team combines a unique mix of deep entrepreneurial and venture capital expertise. We have a history of working together for more than ten years on different types of projects and can present a unique track record in fund-raising, spin-off/venture creation, company growth and successful BD/exit deal making.
Managing Partners
Debbie co-founded Bioqube Ventures in 2015. From 2016-2019, Bioqube Ventures co-managed an investment and incubation model resulting in the set-up and support of a local ecosystem of 10 companies on the Janssen R&D site in Beerse, Belgium. In 2020, Bioqube Ventures launched its first independent fund “Bioqube Factory Fund I”.
Previously, Debbie served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions including XO1 (acquired by Johnson & Johnson), FFPharma and Complix. Prior to joining LRM, between 2007 and 2010, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (currently Happy Aging).
Debbie is vice chairman at the Limburg Cancer Foundation.
PhD in Biomedical Sciences
Hasselt University
MSc Bioscience Engineering
K.U. Leuven
gastronomy, traveling, tennis
Dirk has gained deep commercial experience for more than 25 years at 2 leading pharma companies Eli Lilly and Janssen-Cilag (Johnson & Johnson). He was responsible for the launches and international strategic marketing of different products including Prozac (US/Belgium), Pariet (global) and Prepulsid (global). He was selected for streamlining JNJ’s e-business and became VP for new business development in Europe.
In 2006, Dirk co-founded Movetis NV, a JNJ spin-off for GI assets. As CEO, he was instrumental in raising more than EUR €200 million over four years. Movetis had Resolor (prokinetic) approved in 2009 for chronic constipation and launched in four countries with reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Dirk worked two years for Shire as Managing director for the GI business in Europe.
In 2012 he founded Progress Pharma, an asset development company, with a team of experienced managers. With this team he supported Lipid Therapeutics in a deal with Nestle and co-founded eTheRNA, a spin-off from the University of Brussels with a breakthrough mRNA based immunotherapy for cancer & infectious diseases. In 2018, he worked with the founders as interim CEO of Spectricity, a spin-off from imec. He is board member of Spectricity, chairman of Flanders.bio, the organization of > 300 Flemish biotech companies and Chairman of Across Health, a global health CRM company.
MBA commercial & business engineering
Kellogg’s Chicago
MSc Pharmacist
University of Antwerp
biking, tennis, old-timer rally’s, president of Rotary, president of Moved to Help, organizing music events
Nico co-founded Bioqube Ventures in 2015. From 2016-2019, Bioqube Ventures co-managed an investment and incubation model resulting in the set-up and support of a local ecosystem of 10 companies on the Janssen R&D site in Beerse, Belgium. In 2020, Bioqube Ventures launched its first independent fund “Bioqube Factory Fund I”.
Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.
Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope.
Nico was nominated for the 2018 Bloomberg50 list.
Master’s degree
Commercial & business engineering
Hasselt University
Master in Accountancy
VLEKHO Business School
biking, skiing, gastronomy, sailing, traveling
Investment Team
Joris has 15 years' experience in the pharma-biotech sector, shaping and directing innovative and collaborative R&D programs. Joris joined Bioqube Ventures in 2016, providing strategic R&D advice to international biotech companies.
Previously, Joris had various roles of increasing responsibility in start-ups as well as in large international companies such as Johnson & Johnson, Movetis and Shire Pharmaceuticals, where in his most recent position he served as Director Discovery. Joris also acts as CSO at Facio Therapies.
PhD Medical Sciences
Ghent University
MSc Bio engineering
Applied Biological sciences
University of Leuven
University of Pretoria, South Africa
cooking, playing jazz guitar, jogging, soccer
Joris joined Bioqube Ventures as an immunology expert in 2018. Joris has over 15 years of experience in academic research and is specialized in the fundamental and translational aspects of human immunology.
He started his career as a postdoctoral fellow at the Maastricht University Medical Center developing cellular immunotherapy for cancer. Later he managed several diagnostic programs in the clinic, including kidney transplantation, autoimmunity, immune deficiencies and hematological malignancies.
Training as medical immunologist
CMI
Training as immunologist
SMBWO
PhD Biomedical sciences/immunology
Hasselt University
MSc Biochemistry
KU Leuven
Bachelor Biology
University center of Limburg
outdoor activities, mountain biking, travel, wine-enthusiast
Since joining Bioqube Ventures in October 2017, Alexander has focused on identifying and evaluating investment opportunities within the biotech landscape across various therapeutic areas. He is responsible for providing in-depth competitive analysis and coordinating the investment’s team evaluation process.
Previously, as part of Bioqube Ventures’ previous investment and incubation model, Alexander was involved in working side-by-side with the resident start-up companies. He also co-founded the SINC Alumni network, bringing together entrepreneurial young professionals active across multiple sectors.
MSc Medical Biotechnology and Business Management
University of Warwick
Bachelor Biomedical Sciences
Antwerp University
football, quirky sock collector, furniture design & woodworking
Venture Partners & Operating Partners
Tom Heyman strengthens the Bioqube team leveraging a highly successful track-record gained during his 37 years at Johnson & Johnson. Most recently, Tom served as President of Johnson & Johnson Innovation – JJDC, Inc. (JJDC), leading the corporate venture arm of Johnson & Johnson. In this capacity and chairing the JJDC board, he represented the longest-standing corporate venture fund in the life science industry making strategic investments in healthcare for nearly 46 years. Tom has also engaged in hundreds of transactions involving both early and late stage pharmaceutical products spanning his 25 years in business development. He was responsible for acquiring several key companies for Johnson & Johnson and from 2008 through 2016 he was the CEO of Janssen Pharmaceutica NV in Belgium.
Currently, Tom is Member of the Board of imec vzw (Belgium) and Akero Tx (US).
Post-graduate in Business Management
University of Antwerp
Post-graduate in International Law
Geneva, Switzerland
Master of Law
K.U. Leuven
Tol has over 15 years of experience in the life sciences and venture capital industry. He has strong background in business development and starting up companies. Tol serves and has served in a variety of management capacities, including CEO of Arcarios, COO of Gadeta, founder and general manager at DNage (acquired by Pharming). He has co-founded several companies including Arcarios, Gadeta and CellPoint.
Tol joined Bioqube Ventures as a Venture Partner in 2016.
PhD Molecular Biology
Erasmus University Rotterdam
MSc Biology
Leiden University
MSc Chemistry
Leiden University
skiing, competitive sailing, golf, cooking, flying
Jacques Mizrahi spent the past twenty-five years in drug discovery and translational medicine in several Big Pharma such as GSK, Eli Lilly and Roche where he developed programs in diabetes, renal diseases and cardiovascular diseases. At his last appointment at Roche, he directed the Global Therapy Area of metabolic and cardiovascular diseases focusing on translational medicine programs which included the clinical research on biomarkers and personalized medicine.
Jacques has been a consultant for Aravis Ventures, INSERM Transfer Initiative and ICAN foundation in France. From 2016-2018, Jacques was an Advisor to the Bioqube Ventures team as a member of the Scientific Advisory Committee.
PhD in Physiology-Pharmacology
Medical School of the University of Sherbrooke (Canada)
Post-doctoral fellow
INSERM U36
Advisors
Olivier joined Bioqube as a legal advisor in 2017. He is a partner of Value for Growth, an independent consulting group. Olivier assisted in the creation and development of start-ups, supported companies & organisations with strategy development and implementation and together with leading (investment) banks helped companies with their fund-raising.
Main achievements include assisting with the legal aspects of the creation of the venture capital fund Vesalius Biocapital I & III, co-operating with leading (investment) banks on fund-raising and legal counsel for Selligent, a multinational company of Belgian origin that provides relationship marketing solutions.
Master of Law
University of Louvain / University of Antwerp
Special Licence Tax Law
Université Libre de Bruxelles
Special licence Management
Solvay Business School
Special licence management in the public sector
University of Antwerp
Special licence Environment
University of Antwerp
Ongoing training ICT law
jogging, swimming, Krav Maga, reading, languages, cross-fit, family, gardening
Géry started his career at Janssen in 1990 as a scientist in the department of Bacteriology & Mycology. In 1998, Géry joined Tibotec in the role of team-leader cellular biology. After Tibotec was acquired by Johnson and Johnson, Géry became Associate Director e-Biology, Associate Director Target Validation & Engagement and finally Associate Director hit-to-lead and lead optimization within different discovery capability organizations at Janssen. In October 2017, Géry’s hit-to-lead and Lead optimization team was acquired by Charles River labs.
Géry joined Bioqube Ventures in 2017 as Facility Manager and remains on board as an Advisor to support portfolio companies of the Bioqube Factory Fund.
MSc Biochemistry
Hogeschool West-Brabant
Burotica – Lab computers and operating system
Hoger Instituut Der Kempen
Bachelor in Scientific Informatics
Hoger Instituut Der Kempen
Bachelor in Clinical Chemistry
Hoger Instituut Der Kempen
outdoor activities, getting together with friends, soccer (scout), foodie, Maastricht breakfast
Edouard is acting as a business consultant or coach for companies active in life sciences. As a consultant, he develops market review and segmentation analysis, business plans, company valuation and due diligences. As a coach, he interacts with the project initiator or with team members to assist them in the organization of the business activities. This encompasses the support to start-up a new business, the assistance to negotiate commercial contracts and partnerships, and also the support to professionalize internal procedures.
In addition, Edouard can act in different interim management functions and also performs company reorganizations.
Applied Sciences
Free University of Brussels
Postgraduate degree in Business Administration
Solvay Business School
